A Phase 3 interventional study of glasdegib and daunorubicin + cytarabine in Leukemia, Myeloid, Acute, sponsored by Pfizer. Completed at 149 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute — 11 open to participants now, 16 under way, 4 of them phase 3. Daunorubicin · Leukemia, Myeloid, Acute.
Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, this one is the 5th largest by enrollment of the 48 interventional ones that give a count, is the only one that started in 2018, is one of 11 in phase 3, and was the 36th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →11 of the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Kura Oncology, Inc. · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+
Richard Stone, MD · Sites in United States
Ages 18–75
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18–59
By country, each count listing its studies:
Daunorubicin: first FDA approval 1979 (CERUBIDINE), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 23 · Phase 3 14 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 730 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 111 across the 48 interventional studies. Of the 29 that completed or were terminated, 11 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 50 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
33 studies in Leukemia, Myeloid, Acute by Pfizer: 1 open now, 2 under way, none of them phase 3. Of 29 finished, 13 (45%) have results posted.
Among the 33 studies in Leukemia, Myeloid, Acute by Pfizer, this one has the largest enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2018, is one of 4 in phase 3, and was the 26th registered.
Pfizer’s Leukemia, Myeloid, Acute studies by the year they started, since 1997.
4 of the studies testing daunorubicin in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07561892Fujian Medical University Union HospitalStudy of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). | 2026-12-31 |
| NCT04801797Massachusetts General HospitalVenetoclax + Azacitidine vs. Induction Chemotherapy in AML | 2027-01-01 |
| NCT06313437Richard Stone, MDRevumenib in Combination With 7+3 + Midostaurin in AML | 2027-03-02 |
| NCT05554406National Cancer Institute (NCI)Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, from their registry updates:
Among Pfizer’s 33 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population).
Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).
Two separate registration trials conducted under one protocol number are proposed to adequately and independently evaluate the addition of glasdegib in intensive and non-intensive chemotherapy populations. Each study will have an experimental treatment arm and a placebo arm. Endpoints are the same for each study except where specifically indicated.
Assignment to the Intensive Study or the Non-Intensive Study will be made by the Investigator based on the 2017 European LeukemiaNet (ELN) recommendations.
Study B1371019 is a randomized (1:1), double-blind, multi-center, placebo controlled study of chemotherapy in combination with glasdegib versus chemotherapy in combination with placebo in adult patients with previously untreated AML.
Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population).
Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the Intensive and Non Intensive study (unless where indicated):
Subjects with untreated AML according to the World Health Organization (WHO) 2016 Classification2, including those with:
Adequate Organ Function as defined by the following:
All anti cancer treatments (unless specified) should be discontinued 2 weeks from study entry, for example: targeted chemotherapy, radiotherapy, agents, hormones, anagrelide or cytokines.
Female subjects of non childbearing potential must meet at least 1 of the following criteria:
All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
Exclusion Criteria:
Subjects with any of the following characteristics/conditions will not be included in the study:
AML with BCR ABL1 or t(9;22)(q34;q11.2) as a sole abnormality.
Documented or suspected to any one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glasdegib + '7+3' Induction(s)
Drug: glasdegib · Drug: daunorubicin + cytarabine · Drug: cytarabine · Procedure: HSCT
Placebo + '7+3' Induction(s)
Drug: daunorubicin + cytarabine · Drug: Placebo · Drug: cytarabine · Procedure: HSCT
Glasdegib + azacitidine
Drug: azacitidine · Drug: glasdegib
Placebo + azacitidine
Drug: azacitidine · Drug: Placebo
Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first. Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Also known as: PF-04449913
Drug pages: Daunorubicin · Cytarabine
'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days). If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');
Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first. Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
If required, and done per standard of care post Induction(s).
Intensive Study: Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.
Time frame: Baseline up to 25 months
Non-intensive Study: Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.
Time frame: Baseline up to 25 months
Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 numeric rating scale (NRS), where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.
Time frame: Post-baseline up to Week 8
Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.
Time frame: Post-baseline up to Week 12
Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
Complete remission (CR) was defined based on 2017 European LeukemiaNet (ELN) recommendations. CR: Bone marrow blasts \<5 percentage (%); absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC) greater than equal to (\>=) 1.0\*10\^9/Liter (L); platelet count \>=100\*10\^9/L. CRMRD-neg: CR with negativity for a genetic marker by reverse transcription quantitative polymerase chain reaction (RT-qPCR), or CR with negativity by Multiparameter Flow Cytometry (MFC).
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC less than (\<) 1.0\*10\^9/L; platelet count \<100 × 10\^9/L. CRi (included CR \[includes CRMRD-neg\]): not qualifying for CR, neutropenia \<1.0\*10\^9/L or platelets \<100\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \<1.0\*10\^9/L; platelet count \<100 × 10\^9/L. CRi (included CR \[includes CRMRD-neg\]): not qualifying for CR, neutrophil \<0.5\*10\^9/L or platelets \<50\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts \<5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease \>=10%, and absence of blasts with Auer rods.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts \<5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease \>=10%, and absence of blasts with Auer rods.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Percentage of Participants With Partial Remission (PR)
PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count \>=1.0\*10\^9/L; and platelets count \>=100\*10\^9/L.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Percentage of Participants With Partial Remission (PR)
PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count \>=1.0\*10\^9/L; and platelets count \>=100\*10\^9/L.
Time frame: Day 1 up to maximum of 3 years
Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)
CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Duration of Response (DoRi)
DoRi: only defined for participants who have ever achieved CRi or better (included CR as well) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. CRi: not qualifying for CR, neutropenia \<1.0\*10\^9/L or platelets \<100\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. Participants last known to be alive who were free from relapse after CRi or better were censored at the date of last disease assessment that verifies their status.
Time frame: From date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause (maximum up to 2 years)
Non-intensive Study: Duration of Response (DoRi) or (DoRh)
DoRi: only defined for participants who have ever achieved CRi or better (included CR and CRh) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. DoRh: participants who had ever achieved CRh or better (included CR) on study as the time from date of first achieving CRh or better to the date of disease progression, or relapse after CRh or better, or death due to any cause. CRi: not qualifying for CR, neutrophil \<0.5\*10\^9/L or platelets \<50\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods. CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
Time frame: From date of first achieving CRi/CRh or better to the date of relapse/disease progression after CRi/CRh or better or death due to any cause (maximum up to 3 years)
Non-intensive Study: Time to Response
TTRi:Participants who achieved CRi or better, as the time from date of randomization to first documentation of response(CRi or better).TTRh:Participants who achieved CRh or better, as the time from date of randomization to first documentation of response(CRh or better). CRi:not qualifying for CR, neutrophil\<0.5\*10\^9/L or platelets\<50\*10\^9, absence of extramedullary disease,absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
Time frame: From the date of randomization to the first documentation of response (CRi/CRh or better) (maximum up to 3 years)
Intensive Study: Event-free Survival (EFS)
EFS: Time from the date of randomization to the date of treatment failure (TF), relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L.
Time frame: From the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first (maximum up to 2 years)
Non-intensive Study: Event-free Survival (EFS)
EFS: Time from the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L.
Time frame: From the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first (maximum up to 3 years)
Intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".
Time frame: Day 1 up to maximum of 3 years
Intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL Group. It consists of the EQ-5D descriptive system and a visual analogue scale (VAS), the EuroQoL visual analogue scale (EQ-VAS). EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Participants Global Impression of Symptoms (PGIS)
PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Participants Global Impression of Symptoms (PGIS)
PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Participants Global Impression of Change (PGIC)
PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Participants Global Impression of Change (PGIC)
PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Hematology laboratory test included: anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Hematology laboratory test included: anemia, hemoglobin increased, INR increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, creatine phosphokinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, CPK increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Time frame: Day 1 up to maximum of 3 years
Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
Ctrough of Glasdegib was measured in nanogram per milliliter (ng/mL).
Time frame: Induction, Day 10+/-1: pre-dose, 1, 4 hour (hr); Consolidation phase, Day 1: pre-dose, 1, 4 hr
Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
Ctrough of Glasdegib was measured in ng/mL.
Time frame: Pre-dose: Cycle 1 Day 15 and Cycle 2 Day 1
Intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of \<=450 to \>500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.
Time frame: Day 1 up to maximum of 2 years
Non-intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of \<=450 to \>500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.
Time frame: Day 1 up to maximum of 3 years
This study evaluated glasdegib in intensive and non-intensive chemotherapy populations. Intensive study: Glasdegib was studied in combination with cytarabine and daunorubicin for the treatment of adult participants with previously untreated acute myeloid leukemia (AML). Non-intensive study: Glasdegib was studied in combination with azacitidine for the treatment of adult participants with previously untreated AML who were not candidates for intensive induction chemotherapy.
| Milestone | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|---|---|
| Started | 201 | 203 | 163 | 162 |
| Treated | 198 | 201 | 162 | 160 |
| Completed | 0 | 1 | 13 | 6 |
| Not completed | 201 | 202 | 150 | 156 |
| Withdrew: Death | 90 | 87 | 117 | 113 |
| Withdrew: Withdrawal by subject | 15 | 20 | 6 | 9 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 3 |
| Withdrew: Study participation terminated by sponsor | 93 | 91 | 26 | 31 |
| Withdrew: Other | 2 | 3 | 1 | 0 |
OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.
| months | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Intensive Study: Overall Survival (OS) | 17.3 (15.2 to 18.5) | 20.4 (17.6 to NA) |
OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.
| months | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Non-intensive Study: Overall Survival (OS) | 10.3 (7.7 to 12.4) | 10.6 (8.4 to 13.3) |
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 numeric rating scale (NRS), where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.
| Percentage of participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire | 17.41 (12.17 to 22.66) | 17.24 (12.05 to 22.44) |
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.
| Percentage of participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12 | 11.66 (6.73 to 16.58) | 15.43 (9.87 to 21.00) |
Complete remission (CR) was defined based on 2017 European LeukemiaNet (ELN) recommendations. CR: Bone marrow blasts \<5 percentage (%); absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC) greater than equal to (\>=) 1.0\*10\^9/Liter (L); platelet count \>=100\*10\^9/L. CRMRD-neg: CR with negativity for a genetic marker by reverse transcription quantitative polymerase chain reaction (RT-qPCR), or CR with negativity by Multiparameter Flow Cytometry (MFC).
| Percentage of participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg) | 5.0 (2.4 to 9.0) | 5.4 (2.7 to 9.5) |
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
| Percentage of participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg) | 1.8 (0.4 to 5.3) | 0.6 (0.0 to 3.4) |
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
| Percentage of participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg) | 49.3 (42.1 to 56.4) | 47.3 (40.3 to 54.4) |
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
| Percentage of participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg) | 19.6 (13.8 to 26.6) | 13.0 (8.2 to 19.1) |
CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC less than (\<) 1.0\*10\^9/L; platelet count \<100 × 10\^9/L. CRi (included CR \[includes CRMRD-neg\]): not qualifying for CR, neutropenia \<1.0\*10\^9/L or platelets \<100\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods.
| Percentage of participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi) | 1.5 (0.3 to 4.3) | 5.4 (2.7 to 9.5) |
CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \<1.0\*10\^9/L; platelet count \<100 × 10\^9/L. CRi (included CR \[includes CRMRD-neg\]): not qualifying for CR, neutrophil \<0.5\*10\^9/L or platelets \<50\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods.
| Percentage of participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi) | 2.5 (0.7 to 6.2) | 4.9 (2.2 to 9.5) |
MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts \<5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease \>=10%, and absence of blasts with Auer rods.
| Percentage of participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS) | 1.5 (0.3 to 4.3) | 2.0 (0.5 to 5.0) |
MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts \<5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease \>=10%, and absence of blasts with Auer rods.
| Percentage of participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS) | 3.1 (1.0 to 7.0) | 0.6 (0.0 to 3.4) |
PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count \>=1.0\*10\^9/L; and platelets count \>=100\*10\^9/L.
| Percentage of participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Intensive Study: Percentage of Participants With Partial Remission (PR) | 5.0 (2.4 to 9.0) | 4.4 (2.0 to 8.2) |
PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count \>=1.0\*10\^9/L; and platelets count \>=100\*10\^9/L.
| Percentage of participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Non-intensive Study: Percentage of Participants With Partial Remission (PR) | 2.5 (0.7 to 6.2) | 4.9 (2.2 to 9.5) |
CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
| Percentage of participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh) | 3.1 (1.0 to 7.0) | 3.1 (1.0 to 7.1) |
DoRi: only defined for participants who have ever achieved CRi or better (included CR as well) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. CRi: not qualifying for CR, neutropenia \<1.0\*10\^9/L or platelets \<100\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. Participants last known to be alive who were free from relapse after CRi or better were censored at the date of last disease assessment that verifies their status.
No measurements were reported for this outcome.
DoRi: only defined for participants who have ever achieved CRi or better (included CR and CRh) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. DoRh: participants who had ever achieved CRh or better (included CR) on study as the time from date of first achieving CRh or better to the date of disease progression, or relapse after CRh or better, or death due to any cause. CRi: not qualifying for CR, neutrophil \<0.5\*10\^9/L or platelets \<50\*10\^9, absence of extramedullary disease, and absence of blasts with Auer rods. CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
No measurements were reported for this outcome.
TTRi:Participants who achieved CRi or better, as the time from date of randomization to first documentation of response(CRi or better).TTRh:Participants who achieved CRh or better, as the time from date of randomization to first documentation of response(CRh or better). CRi:not qualifying for CR, neutrophil\<0.5\*10\^9/L or platelets\<50\*10\^9, absence of extramedullary disease,absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L. CRh: MRD (positive or unknown); bone marrow blasts \<5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil \>=0.5\*10\^9/L and platelets \>=50\*10\^9/L must be met, but does not satisfy both neutrophils \>=1\*10\^9/L and platelets \>=100\*10\^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
| Months | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| TTRi | 4.057 ± 1.9532 | 4.093 ± 2.1809 |
| TTRh | 4.334 ± 1.8853 | 4.146 ± 2.1540 |
EFS: Time from the date of randomization to the date of treatment failure (TF), relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L.
No measurements were reported for this outcome.
EFS: Time from the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts \<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC \>=1.0\*10\^9/L; platelet count \>=100\*10\^9/L.
No measurements were reported for this outcome.
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".
No measurements were reported for this outcome.
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".
No measurements were reported for this outcome.
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL Group. It consists of the EQ-5D descriptive system and a visual analogue scale (VAS), the EuroQoL visual analogue scale (EQ-VAS). EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.
No measurements were reported for this outcome.
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.
No measurements were reported for this outcome.
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).
No measurements were reported for this outcome.
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).
No measurements were reported for this outcome.
PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".
No measurements were reported for this outcome.
PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".
No measurements were reported for this outcome.
PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".
No measurements were reported for this outcome.
PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".
No measurements were reported for this outcome.
AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
| Participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| AEs | 196 | 198 |
| SAEs | 86 | 92 |
| Grade 3 or 4 AE | 173 | 169 |
| Grade 5 AE | 16 | 20 |
AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
| Participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| AEs | 161 | 158 |
| SAEs | 117 | 124 |
| Grade 3 or 4 AE | 106 | 100 |
| Grade 5 AE | 50 | 52 |
A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
| Participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Treatment related AEs | 181 | 188 |
| Treatment related SAEs | 48 | 60 |
| Grade 3 or 4 AE | 161 | 149 |
| Grade 5 AE | 5 | 8 |
A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
| Participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Treatment related AEs | 133 | 123 |
| Treatment related SAEs | 45 | 37 |
| Grade 3 or 4 AE | 97 | 72 |
| Grade 5 AE | 4 | 4 |
Hematology laboratory test included: anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
| Participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Anemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 2 |
| Anemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 27 | 14 |
| Anemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 113 | 103 |
| Anemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 4 | 5 |
| Anemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 52 | 73 |
| Hemoglobin increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 2 |
| Hemoglobin increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 194 | 194 |
| Hemoglobin increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 1 |
| INR increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 3 | 1 |
| Lymphocyte count decreased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 2 |
| Lymphocyte count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 4 |
| Lymphocyte count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 21 | 26 |
| Lymphocyte count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 160 | 152 |
| Lymphocyte count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 0 |
| Lymphocyte count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 11 | 9 |
| Lymphocyte count increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 6 |
| Lymphocyte count increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 185 | 180 |
| Lymphocyte count increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 6 | 4 |
| Lymphocyte count increased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 3 |
| Lymphocyte count increased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 0 |
| Neutrophil count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 4 |
| Neutrophil count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 4 | 2 |
| Neutrophil count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 85 | 79 |
| Neutrophil count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 2 |
| Neutrophil count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 105 | 106 |
| Platelet count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 2 |
| Platelet count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 98 | 100 |
| Platelet count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 97 | 95 |
| White blood cell decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 4 |
| White blood cell decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 3 | 2 |
| White blood cell decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 155 | 156 |
| White blood cell decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 37 | 35 |
Hematology laboratory test included: anemia, hemoglobin increased, INR increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
| Participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Anemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 29 | 41 |
| Anemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 97 | 87 |
| Anemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 5 | 1 |
| Anemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 29 | 31 |
| Hemoglobin increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 160 | 159 |
| Hemoglobin increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 1 |
| Lymphocyte count decreased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 0 |
| Lymphocyte count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 0 |
| Lymphocyte count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 96 | 89 |
| Lymphocyte count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 51 | 54 |
| Lymphocyte count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 4 |
| Lymphocyte count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 7 | 13 |
| Lymphocyte count increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 3 | 0 |
| Lymphocyte count increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 147 | 157 |
| Lymphocyte count increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 7 | 3 |
| Lymphocyte count increased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 0 |
| Neutrophil count decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 4 | 0 |
| Neutrophil count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 13 | 22 |
| Neutrophil count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 48 | 40 |
| Neutrophil count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 1 |
| Neutrophil count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 92 | 97 |
| Platelet count decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 21 | 28 |
| Platelet count decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 55 | 64 |
| Platelet count decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 0 |
| Platelet count decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 83 | 68 |
| White blood cell decreased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 0 |
| White blood cell decreased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 0 |
| White blood cell decreased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 43 | 48 |
| White blood cell decreased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 70 | 62 |
| White blood cell decreased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 1 |
| White blood cell decreased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 45 | 48 |
Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, creatine phosphokinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
| Participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Alanine aminotransferase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 1 |
| Alanine aminotransferase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 175 | 184 |
| Alanine aminotransferase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 16 | 13 |
| Alanine aminotransferase increased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 0 |
| Alkaline phosphatase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 3 |
| Alkaline phosphatase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 187 | 192 |
| Alkaline phosphatase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 3 |
| Aspartate aminotransferase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 5 | 2 |
| Aspartate aminotransferase increased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 1 |
| Aspartate aminotransferase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 173 | 186 |
| Aspartate aminotransferase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 15 | 9 |
| Blood bilirubin increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 3 |
| Blood bilirubin increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 184 | 189 |
| Blood bilirubin increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 8 | 5 |
| Blood bilirubin increased: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 1 |
| Chronic kidney disease: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 4 | 5 |
| Chronic kidney disease: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 182 | 188 |
| Chronic kidney disease: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 8 | 4 |
| Chronic kidney disease: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 0 |
| Chronic kidney disease: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 1 |
| CPK increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 20 | 19 |
| CPK increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 161 | 166 |
| CPK increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 0 |
| Creatinine increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 188 | 192 |
| Creatinine increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 7 | 6 |
| GGT increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 5 | 7 |
| GGT increased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 8 | 11 |
| GGT increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 2 |
| Hypercalcemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 5 |
| Hypercalcemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 191 | 192 |
| Hyperglycemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 3 |
| Hyperglycemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 174 | 183 |
| Hyperglycemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 15 | 10 |
| Hyperglycemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 1 |
| Hyperglycemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 1 |
| Hyperkalemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 194 | 194 |
| Hyperkalemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 3 |
| Hyperkalemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 1 |
| Hypermagnesemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 4 |
| Hypermagnesemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 1 |
| Hypermagnesemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 190 | 184 |
| Hypermagnesemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 2 |
| Hypermagnesemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 1 |
| Hypernatremia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 196 | 196 |
| Hypernatremia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 1 |
| Hypernatremia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 1 |
| Hypoalbuminemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 3 |
| Hypoalbuminemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 1 |
| Hypoalbuminemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 185 | 185 |
| Hypoalbuminemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 5 | 8 |
| Hypoalbuminemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 1 |
| Hypocalcemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 5 |
| Hypocalcemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 190 | 189 |
| Hypocalcemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 3 |
| Hypoglycemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 3 |
| Hypoglycemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 193 | 194 |
| Hypoglycemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 1 |
| Hypokalemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 155 | 159 |
| Hypokalemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 41 | 37 |
| Hypokalemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 2 |
| Hypomagnesemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 5 |
| Hypomagnesemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 190 | 187 |
| Hypomagnesemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 0 |
| Hyponatremia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 177 | 188 |
| Hyponatremia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 17 | 8 |
| Hyponatremia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 1 |
| Hyponatremia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 1 |
| Hypophosphatemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 3 | 3 |
| Hypophosphatemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 1 |
| Hypophosphatemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 153 | 153 |
| Hypophosphatemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade | 33 | 33 |
| Hypophosphatemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 2 |
| Hypophosphatemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 3 | 1 |
Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, CPK increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
| Participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Alanine aminotransferase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 0 |
| Alanine aminotransferase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 152 | 154 |
| Alanine aminotransferase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 6 | 6 |
| Alanine aminotransferase increased: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 0 |
| Alkaline phosphatase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 1 |
| Alkaline phosphatase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 159 | 157 |
| Alkaline phosphatase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 1 |
| Aspartate aminotransferase increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 3 | 0 |
| Aspartate aminotransferase increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 152 | 156 |
| Aspartate aminotransferase increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 4 | 4 |
| Blood bilirubin increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 157 | 159 |
| Blood bilirubin increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 3 | 1 |
| Chronic kidney disease: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 1 |
| Chronic kidney disease: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 130 | 134 |
| Chronic kidney disease: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 28 | 23 |
| Chronic kidney disease: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 2 |
| CPK increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 9 | 8 |
| CPK increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 147 | 147 |
| CPK increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 2 |
| Creatinine increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 153 | 155 |
| Creatinine increased: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 7 | 5 |
| GGT increased: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 3 | 5 |
| GGT increased: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 4 | 3 |
| GGT increased: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 0 |
| Hypercalcemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 2 |
| Hypercalcemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 156 | 158 |
| Hyperglycemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 4 |
| Hyperglycemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 147 | 136 |
| Hyperglycemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 8 | 14 |
| Hyperglycemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 2 |
| Hyperkalemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 0 |
| Hyperkalemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 155 | 157 |
| Hyperkalemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 3 |
| Hyperkalemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 0 |
| Hyperkalemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 0 |
| Hypermagnesemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 4 |
| Hypermagnesemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 155 | 154 |
| Hypermagnesemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 2 |
| Hypernatremia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 158 | 159 |
| Hypernatremia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 2 | 1 |
| Hypoalbuminemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 0 |
| Hypoalbuminemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 151 | 157 |
| Hypoalbuminemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 6 | 3 |
| Hypocalcemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 2 |
| Hypocalcemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 154 | 155 |
| Hypocalcemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 3 |
| Hypocalcemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 0 | 0 |
| Hypoglycemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 4 |
| Hypoglycemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 155 | 156 |
| Hypoglycemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 3 | 0 |
| Hypokalemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 0 |
| Hypokalemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 129 | 139 |
| Hypokalemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 23 | 15 |
| Hypokalemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 1 | 2 |
| Hypokalemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 4 | 4 |
| Hypomagnesemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 2 | 4 |
| Hypomagnesemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 151 | 153 |
| Hypomagnesemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 6 | 2 |
| Hypomagnesemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 1 |
| Hyponatremia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 135 | 142 |
| Hyponatremia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade) | 24 | 15 |
| Hyponatremia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 1 |
| Hyponatremia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 2 |
| Hypophosphatemia: Missing (baseline grade) to Grade <=2 (CTCAE grade) | 3 | 2 |
| Hypophosphatemia: Missing (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 0 |
| Hypophosphatemia: Grade <=2 (baseline grade) to Grade <=2 (CTCAE grade) | 141 | 138 |
| Hypophosphatemia: Grade <=2 (baseline grade) to Grade 3/4 (CTCAE grade | 12 | 17 |
| Hypophosphatemia: Grade 3/4 (baseline grade) to Grade <=2 (CTCAE grade) | 0 | 1 |
| Hypophosphatemia: Grade 3/4 (baseline grade) to Grade 3/4 (CTCAE grade) | 1 | 2 |
Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
| Participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| Activated partial thromboplastin time prolonged: Missing (baseline grade) to Grade 0 (CTCAE grade) | 1 | 0 |
| Activated partial thromboplastin time prolonged: Missing (baseline grade) to Grade 1 (CTCAE grade) | 0 | 1 |
| Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 0 (CTCAE grade) | 0 | 4 |
| Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 1 (CTCAE grade) | 1 | 2 |
| Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 2 (CTCAE grade) | 0 | 1 |
| Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 3 (CTCAE grade) | 1 | 0 |
| Activated partial thromboplastin time prolonged: Grade 1 (baseline grade) to Grade 1 (CTCAE grade) | 1 | 1 |
| INR increased: Missing (baseline grade) to Grade 0 (CTCAE grade) | 1 | 1 |
| INR increased: Missing (baseline grade) to Grade 1 (CTCAE grade) | 0 | 1 |
| INR increased: Missing (baseline grade) to Grade 2 (CTCAE grade) | 1 | 0 |
| INR increased: Grade 0 (baseline grade) to Grade 0 (CTCAE grade) | 0 | 2 |
| INR increased: Grade 0 (baseline grade) to Grade 1 (CTCAE grade) | 1 | 0 |
| INR increased: Grade 0 (baseline grade) to Grade 2 (CTCAE grade) | 1 | 1 |
| INR increased: Grade 0 (baseline grade) to Grade 3 (CTCAE grade) | 0 | 1 |
| INR increased: Grade 1 (baseline grade) to Grade 0 (CTCAE grade) | 0 | 1 |
| INR increased: Grade 1 (baseline grade) to Grade 1 (CTCAE grade) | 0 | 3 |
| INR increased: Grade 1 (baseline grade) to Grade 2 (CTCAE grade) | 1 | 1 |
| INR increased: Grade 1 (baseline grade) to Grade 3 (CTCAE grade) | 1 | 0 |
Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
| Participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| Activated partial thromboplastin time prolonged: Missing (baseline grade) to Grade 0 (CTCAE grade) | 1 | 0 |
| Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 0 (CTCAE grade) | 8 | 5 |
| Activated partial thromboplastin time prolonged: Grade 0 (baseline grade) to Grade 1 (CTCAE grade) | 5 | 7 |
| Activated partial thromboplastin time prolonged: Grade 1 (baseline grade) to Grade 0 (CTCAE grade) | 1 | 0 |
| Activated partial thromboplastin time prolonged: Grade 1 (baseline grade) to Grade 1 (CTCAE grade) | 1 | 0 |
| Activated partial thromboplastin time prolonged: Grade 2 (baseline grade) to Grade 1 (CTCAE grade) | 1 | 0 |
| INR increased: Missing (baseline grade) to Grade 0 (CTCAE grade) | 1 | 0 |
| INR increased: Grade 0 (baseline grade) to Grade 0 (CTCAE grade) | 4 | 5 |
| INR increased: Grade 0 (baseline grade) to Grade 1 (CTCAE grade) | 6 | 4 |
| INR increased: Grade 0 (baseline grade) to Grade 2 (CTCAE grade) | 1 | 2 |
| INR increased: Grade 0 (baseline grade) to Grade 3 (CTCAE grade) | 1 | 0 |
| INR increased: Grade 1 (baseline grade) to Grade 1 (CTCAE grade) | 1 | 1 |
| INR increased: Grade 1 (baseline grade) to Grade 2 (CTCAE grade) | 2 | 0 |
| INR increased: Grade 3 (baseline grade) to Grade 1 (CTCAE grade) | 1 | 1 |
Ctrough of Glasdegib was measured in nanogram per milliliter (ng/mL).
| ng/ml | Intensive Study: Glasdegib + Cytarabine + Daunorubicin |
|---|---|
| Induction Day 10 | 413.54 ± 125 |
| Consolidation 1, Day 1 | 245.48 ± 80 |
| Consolidation 2, Day 1 | 259.79 ± 122 |
Ctrough of Glasdegib was measured in ng/mL.
| ng/ml | Non-intensive Study: Glasdegib + Azacitidine |
|---|---|
| Cycle 1 Day 15 | 565.44 ± 126 |
| Cycle 2 Day 1 | 472.42 ± 122 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of \<=450 to \>500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.
| Participants | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin |
|---|---|---|
| QTcB: <=450 msec (baseline) to <=450 msec (post-baseline) | 51 | 71 |
| QTcB: <=450 msec (baseline) to >450-<=480 msec (post-baseline) | 64 | 63 |
| QTcB: <=450 msec (baseline) to >480-<=500 msec (post-baseline) | 18 | 11 |
| QTcB: <=450 msec (baseline) to >500 msec (post-baseline) | 11 | 6 |
| QTcB: >450-<=480 msec (baseline) to <=450 msec (post-baseline) | 2 | 3 |
| QTcB: >450-<=480 msec (baseline) to >450-<=480 msec (post-baseline) | 20 | 17 |
| QTcB: >450-<=480 msec (baseline) to >480-<=500 msec (post-baseline) | 16 | 10 |
| QTcB: >450-<=480 msec (baseline) to >500 msec (post-baseline) | 1 | 5 |
| QTcB: >480-<=500 msec (baseline) to >450-<=480 msec (post-baseline) | 1 | 0 |
| QTcB: >480-<=500 msec (baseline) to >480-<=500 msec (post-baseline) | 2 | 1 |
| QTcB: >480-<=500 msec (baseline) to >500 msec (post-baseline) | 1 | 0 |
| QTcB: >500 msec (baseline) to >500 msec (post-baseline) | 1 | 1 |
| QTcF: <=450 msec (baseline) to <=450 msec (post-baseline) | 116 | 132 |
| QTcF: <=450 msec (baseline) to >450-<=480 msec (post-baseline) | 50 | 39 |
| QTcF: <=450 msec (baseline) to >480-<=500 msec (post-baseline) | 8 | 10 |
| QTcF: <=450 msec (baseline) to >500 msec (post-baseline) | 5 | 0 |
| QTcF: >450-<=480 msec (baseline) to <=450 msec (post-baseline) | 2 | 1 |
| QTcF: >450-<=480 msec (baseline) to >450-<=480 msec (post-baseline) | 5 | 5 |
| QTcF: >450-<=480 msec (baseline) to >500 msec (post-baseline) | 1 | 1 |
| QTcF: >480-<=500 msec (baseline) to >480-<=500 msec (post-baseline) | 0 | 1 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of \<=450 to \>500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.
| Participants | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|
| QTcB: <=450 msec (baseline) to <=450 msec (post-baseline) | 48 | 58 |
| QTcB: <=450 msec (baseline) to >450-<=480 msec (post-baseline) | 53 | 43 |
| QTcB: <=450 msec (baseline) to >480-<=500 msec (post-baseline) | 6 | 11 |
| QTcB: <=450 msec (baseline) to >500 msec (post-baseline) | 7 | 3 |
| QTcB: >450-<=480 msec (baseline) to <=450 msec (post-baseline) | 0 | 1 |
| QTcB: >450-<=480 msec (baseline) to >450-<=480 msec (post-baseline) | 20 | 22 |
| QTcB: >450-<=480 msec (baseline) to >480-<=500 msec (post-baseline) | 13 | 8 |
| QTcB: >450-<=480 msec (baseline) to >500 msec (post-baseline) | 5 | 3 |
| QTcB: >480-<=500 msec (baseline) to >450-<=480 msec (post-baseline) | 1 | 2 |
| QTcB: >480-<=500 msec (baseline) to >480-<=500 msec (post-baseline) | 3 | 1 |
| QTcB: >480-<=500 msec (baseline) to >500 msec (post-baseline) | 2 | 3 |
| QTcF: <=450 msec (baseline) to <=450 msec (post-baseline) | 100 | 104 |
| QTcF: <=450 msec (baseline) to >450-<=480 msec (post-baseline) | 39 | 36 |
| QTcF: <=450 msec (baseline) to >480-<=500 msec (post-baseline) | 7 | 0 |
| QTcF: >450 - <=480 (baseline) to <=450msec (post-baseline) | 1 | 1 |
| QTcF: >450 - <=480 msec (baseline) to >450 - <=480msec(post baseline) | 0 | 1 |
| QTcF: >450 - <=480 msec (baseline) to >480 - <=500 msec (post baseline) | 5 | 8 |
| QTcF: >480 msec (baseline) to <=500 msec (post baseline) | 1 | 4 |
| QTcF: >450 - <=480 (baseline) to >500 msec (post baseline) | 1 | 1 |
| QTcF: >480 - <=500msec (baseline) to >480 - <=500 msec (post baseline) | 1 | 0 |
Collected over Intensive study: Day 1 up to maximum of 2 years; non-intensive study: Day 1 up to maximum of 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intensive Study: Glasdegib + Cytarabine + Daunorubicin | 90/201 (44.8%) | 86/198 (43.4%) | 194/198 (98%) |
| Intensive Study: Placebo + Cytarabine + Daunorubicin | 88/203 (43.3%) | 92/201 (45.8%) | 195/201 (97%) |
| Non-intensive Study: Glasdegib + Azacitidine | 117/163 (71.8%) | 117/162 (72.2%) | 154/162 (95.1%) |
| Non-intensive Study: Placebo + Azacitidine | 113/162 (69.8%) | 124/160 (77.5%) | 148/160 (92.5%) |
| Event | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 15/198 | 11/201 | 29/162 | 36/160 |
| Febrile neutropeniaBlood and lymphatic system disorders | 18/198 | 17/201 | 24/162 | 20/160 |
| Disease progressionGeneral disorders | 2/198 | 5/201 | 14/162 | 22/160 |
| SepsisInfections and infestations | 15/198 | 13/201 | 14/162 | 10/160 |
| PyrexiaGeneral disorders | 4/198 | 6/201 | 11/162 | 11/160 |
| Electrocardiogram QT prolongedInvestigations | 13/198 | 8/201 | 5/162 | 3/160 |
| Urinary tract infectionInfections and infestations | 0/198 | 1/201 | 9/162 | 4/160 |
| CellulitisInfections and infestations | 1/198 | 0/201 | 2/162 | 7/160 |
| Septic shockInfections and infestations | 2/198 | 4/201 | 4/162 | 7/160 |
| AnaemiaBlood and lymphatic system disorders | 2/198 | 1/201 | 6/162 | 5/160 |
| Event | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 110/198 | 106/201 | 58/162 | 44/160 |
| AnaemiaBlood and lymphatic system disorders | 101/198 | 97/201 | 73/162 | 71/160 |
| Febrile neutropeniaBlood and lymphatic system disorders | 97/198 | 96/201 | 23/162 | 22/160 |
| DiarrhoeaGastrointestinal disorders | 96/198 | 88/201 | 39/162 | 32/160 |
| PyrexiaGeneral disorders | 84/198 | 84/201 | 42/162 | 38/160 |
| HypokalaemiaMetabolism and nutrition disorders | 76/198 | 83/201 | 35/162 | 22/160 |
| Platelet count decreasedInvestigations | 77/198 | 73/201 | 30/162 | 26/160 |
| ConstipationGastrointestinal disorders | 71/198 | 61/201 | 58/162 | 52/160 |
| White blood cell count decreasedInvestigations | 63/198 | 53/201 | 17/162 | 18/160 |
| VomitingGastrointestinal disorders | 57/198 | 40/201 | 35/162 | 32/160 |
Full analysis (FA) set included all randomized participants.
| Age, Continuous(years) | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine | Total |
|---|---|---|---|---|---|
| Mean | 56.55 ± 12.60 | 55.38 ± 13.61 | 73.19 ± 7.17 | 73.14 ± 6.82 | 63.63 ± 13.79 |
| Sex: Female, Male(Participants) | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine | Total |
|---|---|---|---|---|---|
| Female | 71 | 97 | 97 | 89 | 354 |
| Male | 130 | 106 | 66 | 73 | 375 |
| Ethnicity (NIH/OMB)(Participants) | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 19 | 12 | 12 | 16 | 59 |
| Not Hispanic or Latino | 166 | 171 | 140 | 139 | 616 |
| Unknown or Not Reported | 16 | 20 | 11 | 7 | 54 |
| Race (NIH/OMB)(Participants) | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | Intensive Study: Placebo + Cytarabine + Daunorubicin | Non-intensive Study: Glasdegib + Azacitidine | Non-intensive Study: Placebo + Azacitidine | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 66 | 57 | 51 | 44 | 218 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 1 | 7 | 14 |
| White | 110 | 123 | 97 | 99 | 429 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 20 | 20 | 14 | 12 | 66 |
Showing the first 100 of 149 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2018 to primary completion in Jun 2020, 25 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 25 months is below that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glasdegib · Daunorubicin · Cytarabine · Azacitidine